Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma

Table 4 Variables associated with treatment duration

Variables	Univariate		Multivariate
	HR (95%CI)	P value	HR (95%CI)	P value
Age ≤ 70 yr (vs > 70 yr)	0.543 (0.257-1.147)	0.110
Other etiologies (vs HCV infection)	0.411 (0.191-0.886)	0.023
DCP ≤ 1000 mAU/mL (vs > 1000 mAU/mL)	0.402 (0.190-0.851)	0.017
Nursing intervention yes (vs no)	0.577 (0.278-1.198)	0.140	0.398 (0.181-0.874)	0.022
Efficacy, disease control (vs PD)	0.431 (0.206-0.903)	0.026
Adverse events > grade 2 + (vs -)
Skin toxicitya	0.306 (0.139-0.675)	0.003	0.225 (0.095-0.534)	0.001
Diarrhea	0.352 (0.156-0.796)	0.012
Weight loss	0.555 (0.254-1.213)	0.140
Alopecia	0.236 (0.081-0.686)	0.008

^aSkin toxicity includes hand-oot skin reaction and any kind of rash. HR: Hazard ratio; HCV: Hepatitis C virus; DCP: Des-gamma-carboxy prothrombin.This table only includes variables with P values < 0.15 in univariate analyses.